Povorcitinib

DB18855InvestigationalSmall molecule

Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)).

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK1
Curator reviewed
Formula / weight: C₂₃H₂₂F₅N₇O · 507.469 g/mol (avg)
Code names: INCB054707

Resolves to

Compound

UNIIN0JWC7RO00CAS1637677-22-5

Structure

InChIKeyMSGYSFWCPOBHEV-AWEZNQCLSA-NSMILESC[C@H](NC(=O)C1=CC(F)=C(C=C1F)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C(C)NN=C1C)C(F)(F)F

Targets

P23458JAK1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

16Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Povorcitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account